BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.

Borthakur G, Ofran Y, Tallman MS, Foran J, Uy GL, DiPersio JF, Showel MM, Shimoni A, Nagler A, Rowe JM, Altman JK, Abraham M, Peled A, Shaw S, Bohana-Kashtan O, Sorani E, Pereg Y, Foley-Comer A, Oberkovitz G, Lustig TM, Glicko-Kabir I, Aharon A, Vainstein-Haras A, Kadosh SE, Samara E, Al-Rawi AN, Pemmaraju N, Bueso-Ramos C, Cortes JE, Andreeff M

Open source

DOI: 10.1002/cncr.33338
Published: 2021 Apr 15
Container: Cancer
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/cncr.33338,
  title = {BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.},
  author = {Borthakur G and Ofran Y and Tallman MS and Foran J and Uy GL and DiPersio JF and Showel MM and Shimoni A and Nagler A and Rowe JM and Altman JK and Abraham M and Peled A and Shaw S and Bohana-Kashtan O and Sorani E and Pereg Y and Foley-Comer A and Oberkovitz G and Lustig TM and Glicko-Kabir I and Aharon A and Vainstein-Haras A and Kadosh SE and Samara E and Al-Rawi AN and Pemmaraju N and Bueso-Ramos C and Cortes JE and Andreeff M},
  year = {2021},
  journal = {Cancer},
  doi = {10.1002/cncr.33338},
  url = {https://doi.org/10.1002/cncr.33338}
}

RIS

TY  - JOUR
TI  - BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.
AU  - Borthakur G
AU  - Ofran Y
AU  - Tallman MS
AU  - Foran J
AU  - Uy GL
AU  - DiPersio JF
AU  - Showel MM
AU  - Shimoni A
AU  - Nagler A
AU  - Rowe JM
AU  - Altman JK
AU  - Abraham M
AU  - Peled A
AU  - Shaw S
AU  - Bohana-Kashtan O
AU  - Sorani E
AU  - Pereg Y
AU  - Foley-Comer A
AU  - Oberkovitz G
AU  - Lustig TM
AU  - Glicko-Kabir I
AU  - Aharon A
AU  - Vainstein-Haras A
AU  - Kadosh SE
AU  - Samara E
AU  - Al-Rawi AN
AU  - Pemmaraju N
AU  - Bueso-Ramos C
AU  - Cortes JE
AU  - Andreeff M
PY  - 2021
JO  - Cancer
DO  - 10.1002/cncr.33338
UR  - https://doi.org/10.1002/cncr.33338
ER  -

APA

G, B., Y, O., MS, T., J, F., GL, U., JF, D., MM, S., A, S., A, N., JM, R., JK, A., M, A., A, P., S, S., O, B., E, S., Y, P., A, F., G, O., TM, L., I, G., A, A., A, V., SE, K., E, S., AN, A., N, P., C, B., JE, C., & M, A. (2021). BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.. Cancer. https://doi.org/10.1002/cncr.33338

Source records

pubmed · retrieved 2026-09-25T13:29:29.125Z
europe-pmc · retrieved 2026-09-25T13:29:29.142Z